This phase III study, open-label, randomized study investigating lenalidomide and
dexamethasone with and without biaxin in subjects with newly diagnosed, previously untreated
MM. Eligible subjects will be randomized in a 1:1 ratio to receive a regimen consisting of
either biaxin, lenalidomide, and low-dose dexamethasone (BiRd arm), or lenalidomide and
low-dose dexamethasone (Rd arm). 306 patients will be included (50% in Spain (153) and 50% in
the USA (153)